StockpollyBeta
Get App
Popularity #1,371
CABA · NASDAQ · Biotechnology

Cabaletta Bio (CABA)

Develops engineered T-cell therapies for autoimmune disease, prioritizing rese-cel.

$2.51
After hours+0.01 (+0.59%)
At close$2.50(+1.42%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
192328303334374647434452
Research & development141722232626293840363744
566778887678
General & administrative566778887678
Operating income−19−23−28−30−33−34−37−46−47−43−44−52
223321112111
Interest income223322112112
Interest expense000001011111
Other non-operating income0−2−3−3−2−10−1−1−2−1−1−2
Income before tax−16−21−25−28−31−33−36−45−45−42−44−51
Net income from continuing operations−16−21−25−28−31−33−36−45−45−42−44−51
Net income−16−21−25−28−31−33−36−45−45−42−44−51
EPS, basic−$0.37−$0.47−$0.50−$0.56−$0.63−$0.65−$0.73−$0.73−$0.44−$0.41−$0.39−$0.34
EPS, diluted−$0.37−$0.47−$0.51−$0.56−$0.62−$0.65−$0.73−$0.73−$0.44−$0.41−$0.39−$0.34
Weighted average shares, basic4444494949504962102102112151
Weighted average shares, diluted4444494949504962102102112151
EBITDA−18−21−25−27−30−23−35−44−44−41−43−49
Depreciation & amortization000000000001
EBIT−19−21−25−28−31−24−36−45−44−41−43−51